Secondary endpoints: details revised at 3 of 19 entries
MinorTrial sites expanded: 8 → 11 locationsv3
NotableRecruitment opened
Trial sites expanded: 0 → 8 locations
Start date changed from estimate of Jul 2026 to Jul 29, 2026
v2
Study First Submitted
Notable: the plan changed
Minor: routine updates
Endpoints
Primary
Phase 2: Part A: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm
Timeframe: Week 35
Phase 2: Part B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA Snapshot Algorithm
Timeframe: Week 26
Phase 3: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm
Timeframe: Week 52
Secondary (19)
Phase 2: Parts A and B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 as Determined by the US FDA Snapshot Algorithm
Phase 2: Parts A and B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm
Phase 2: Parts A and B: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 12
Phase 2: Part A: Change From Baseline in CD4 Cell Count at Week 35
Phase 2: Parts A and B: Change From Baseline in CD4 Cell Count at Week 52
Show 14 moreShow less
Phase 2: Part B: Change From Baseline in CD4 Cell Count at Week 26
Phase 2: Parts A and B: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 12
Phase 2: Part A: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 35
Phase 2: Part B: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 26
Phase 2: Parts A and B and Phase 3: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 52
Phase 2: Part A: Groups 1 and 2: Trough Concentrations of GS-3242 and LEN at Week 18
Phase 2: Part A: Groups 1 and 2: Trough Concentrations of GS-3242 and LEN at Week 35
Phase 2: Part A and Part B: Trough Concentrations of GS-3242 and LEN at Week 52
Phase 2: Part B: Trough Concentrations of GS-3242 and LEN at Week 26
Phase 3: Proportion of Participants with HIV-1 RNA < 50 copies/mL at Week 104 as determined by the US FDA snapshot algorithm
Phase 3: Change From Baseline in CD4 Cell Count at Week 52
Phase 3: Change From Baseline in CD4 Cell Count at Week 104
Phase 3: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 52
Phase 3: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 104
Arms and interventions
Phase 2: Part A: Group 1 of GS-3242 + LENExperimental
Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by intramuscular (IM) injections of GS-3242 and LEN for at least 52 weeks.
Phase 2: Part A: Group 2 of GS-3242 + LENExperimental
Participants will be randomized oral loading doses of GS-3242 in combination with LEN oral tablets, followed by IM injections of GS-3242 (at a different dose than Group 1) and LEN for at least 52 weeks.
Phase 2: Part A: Group 3 of B/F/TAFExperimental
Participants will be randomized to receive 50/200/25 mg of B/F/TAF daily for at least 52 weeks.
Phase 2: Part B: Group 4 of GS-3242 + LENExperimental
Participants will be enrolled (non-randomized) to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed IM injections of GS-3242 and LEN (at different doses than Group 1 and 2) for at least 52 weeks.
Phase 3: Group 1 of GS-3242 + LENExperimental
Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by IM injections of GS-3242 and LEN for at least 104 weeks.
Phase 3: Group 2 of B/F/TAFExperimental
Participants will be randomized to receive 50/200/25 mg of B/F/TAF daily for at least 104 weeks.